BACKGROUND: Glucosaminidase (Gmd) is known to be a protective antigen in animal models of Staphylococcus aureus osteomyelitis. We compared the endogenous anti-Gmd antibody levels in sera of patients with culture-confirmed S. aureus bone infections to their sera at 1 year after operative treatment of the infection. METHODS: A novel global biospecimen registry of 297 patients with deep-wound culture-confirmed S. aureus osteomyelitis was analyzed to assess relationships between baseline anti-Gmd serum titers (via custom Luminex assay), known host risk factors for infection, and 1-year postoperative clinical outcomes (e.g., infection control, inconclusive, refracture, persistent infection, septic nonunion, amputation, and septic death). RESULTS: All patients had measurable humoral immunity against some S. aureus antigens, but only 20 patients (6.7%; p < 0.0001) had high levels of anti-Gmd antibodies (>10 ng/mL) in serum at baseline. A subset of 194 patients (65.3%) who completed 1 year of follow-up was divided into groups based on anti-Gmd level: low (<1 ng/mL, 54 patients; 27.8%), intermediate (<10 ng/mL, 122 patients; 62.9%), and high (>10 ng/mL, 18 patients; 9.3%), and infection control rates were 40.7%, 50.0%, and 66.7%, respectively. The incidence of adverse outcomes in these groups was 33.3%, 16.4%, and 11.1%, respectively. Assessing anti-Gmd level as a continuous variable showed a 60% reduction in adverse-event odds (p = 0.04) for every tenfold increase in concentration. No differences in patient demographics, body mass index of >40 kg/m, diabetes status, age of ≥70 years, male sex, Charlson Comorbidity Index of >1, or Cierny-Mader host type were observed between groups, and these risk factors were not associated with adverse events. Patients with low anti-Gmd titer demonstrated a significant 2.68-fold increased odds of adverse outcomes (p = 0.008). CONCLUSIONS: Deficiency in circulating anti-Gmd antibodies was associated serious adverse outcomes following operative treatment of S. aureus osteomyelitis. At 1 year, high levels of anti-Gmd antibodies were associated with a nearly 3-fold increase in infection-control odds. Additional prospective studies clarifying Gmd immunization for osteomyelitis are needed. LEVEL OF EVIDENCE: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
BACKGROUND: Glucosaminidase (Gmd) is known to be a protective antigen in animal models of Staphylococcus aureus osteomyelitis. We compared the endogenous anti-Gmd antibody levels in sera of patients with culture-confirmed S. aureus bone infections to their sera at 1 year after operative treatment of the infection. METHODS: A novel global biospecimen registry of 297 patients with deep-wound culture-confirmed S. aureus osteomyelitis was analyzed to assess relationships between baseline anti-Gmd serum titers (via custom Luminex assay), known host risk factors for infection, and 1-year postoperative clinical outcomes (e.g., infection control, inconclusive, refracture, persistent infection, septic nonunion, amputation, and septic death). RESULTS: All patients had measurable humoral immunity against some S. aureus antigens, but only 20 patients (6.7%; p < 0.0001) had high levels of anti-Gmd antibodies (>10 ng/mL) in serum at baseline. A subset of 194 patients (65.3%) who completed 1 year of follow-up was divided into groups based on anti-Gmd level: low (<1 ng/mL, 54 patients; 27.8%), intermediate (<10 ng/mL, 122 patients; 62.9%), and high (>10 ng/mL, 18 patients; 9.3%), and infection control rates were 40.7%, 50.0%, and 66.7%, respectively. The incidence of adverse outcomes in these groups was 33.3%, 16.4%, and 11.1%, respectively. Assessing anti-Gmd level as a continuous variable showed a 60% reduction in adverse-event odds (p = 0.04) for every tenfold increase in concentration. No differences in patient demographics, body mass index of >40 kg/m, diabetes status, age of ≥70 years, male sex, Charlson Comorbidity Index of >1, or Cierny-Mader host type were observed between groups, and these risk factors were not associated with adverse events. Patients with low anti-Gmd titer demonstrated a significant 2.68-fold increased odds of adverse outcomes (p = 0.008). CONCLUSIONS: Deficiency in circulating anti-Gmd antibodies was associated serious adverse outcomes following operative treatment of S. aureus osteomyelitis. At 1 year, high levels of anti-Gmd antibodies were associated with a nearly 3-fold increase in infection-control odds. Additional prospective studies clarifying Gmd immunization for osteomyelitis are needed. LEVEL OF EVIDENCE: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
Authors: Dan Li; Kirill Gromov; Kjeld Søballe; J Edward Puzas; Regis J O'Keefe; Hani Awad; Hicham Drissi; Edward M Schwarz Journal: J Orthop Res Date: 2008-01 Impact factor: 3.494
Authors: T Ferry; I Uçkay; P Vaudaux; P François; J Schrenzel; S Harbarth; F Laurent; L Bernard; F Vandenesch; J Etienne; P Hoffmeyer; D Lew Journal: Eur J Clin Microbiol Infect Dis Date: 2009-11-28 Impact factor: 3.267
Authors: Jonah J Stulberg; Conor P Delaney; Duncan V Neuhauser; David C Aron; Pingfu Fu; Siran M Koroukian Journal: JAMA Date: 2010-06-23 Impact factor: 56.272
Authors: Malley A Gautreaux; Luke J Tucker; Xavier J Person; Haley K Zetterholm; Lauren B Priddy Journal: J Orthop Res Date: 2022-04-03 Impact factor: 3.102
Authors: Wei Fu; Wenbin He; Youliang Ren; Zhengdao Li; Jinyue Liu; Yi Liu; Zhao Xie; Jianzhong Xu; Qing Bi; Mingxiang Kong; Charles C Lee; John L Daiss; Gowrishankar Muthukrishnan; John R Owen; Stephen L Kates; Jiachen Peng; Chao Xie Journal: J Orthop Res Date: 2020-12-29 Impact factor: 3.494
Authors: Gowrishankar Muthukrishnan; Christopher A Beck; John R Owen; Chao Xie; Stephen L Kates; John L Daiss Journal: J Orthop Res Date: 2020-12-25 Impact factor: 3.102
Authors: J R Owen; M P Campbell; M D Mott; C A Beck; C Xie; G Muthukrishnan; J L Daiss; E M Schwarz; S L Kates Journal: Eur Cell Mater Date: 2021-09-22 Impact factor: 3.942
Authors: Elysia A Masters; Benjamin F Ricciardi; Karen L de Mesy Bentley; T Fintan Moriarty; Edward M Schwarz; Gowrishankar Muthukrishnan Journal: Nat Rev Microbiol Date: 2022-02-15 Impact factor: 78.297
Authors: Shardulendra Prasad Sherchand; Rajan P Adhikari; Gowrishankar Muthukrishnan; Tulasikumari Kanipakala; John R Owen; Chao Xie; M Javad Aman; Richard A Proctor; Edward M Schwarz; Stephen L Kates Journal: Front Cell Infect Microbiol Date: 2022-07-18 Impact factor: 6.073
Authors: Kohei Nishitani; Masahiro Ishikawa; Yugo Morita; Noriaki Yokogawa; Chao Xie; Karen L de Mesy Bentley; Hiromu Ito; Stephen L Kates; John L Daiss; Edward M Schwarz Journal: JCI Insight Date: 2020-10-02